Search
Ubidecarenone
go.drugbank.com/drugs/DB09270ApprovedInvestigationalNutraceuticalUbidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid...
Categories: P-glycoprotein substratesTenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigationalTenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on te...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesEsterified estrogens
go.drugbank.com/drugs/DB09381ApprovedEsterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterifi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNorgestrel
go.drugbank.com/drugs/DB09389ApprovedNorgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center, it is considered a boronate proteasome inhibitor. More than 99% of the drug compound is the R-enantiomer. Ixazomib was a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesElbasvir
go.drugbank.com/drugs/DB11574ApprovedElbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is c...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was ap...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can e...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates